Israel's Exalenz Diagnostic To Be Used In Pfizer U.S. Hep C Trials
This article was originally published in PharmAsia News
Exalenz Bioscience of Israel has entered into an agreement with U.S.-based Pfizer to use a diagnostic in a mid-stage trial to treat hepatitis C
You may also be interested in...
Sanofi has transformed the productivity of its R&D pipeline over the past several years, and late-stage clinical data readouts are expected in the second half of this year for new anticancer drugs, a candidate pemphigus therapy and a COVID-19 vaccine.
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.
The EU marketing authorization application for Takeda's dengue vaccine candidate is no longer being fast-tracked. Also, five requests for accelerated assessment were decided on at the latest meeting of the European Medicines Agency's drug evaluation committee, the CHMP.